Research opens door to vaccines that can circumvent maternal antibodies

New research that reveals how maternal antibodies block an immune response to the measles virus is a first step toward improving current childhood vaccination practices, scientists say.

Maternal antibodies are passed to fetuses during pregnancy and to newborns in their mothers' milk. The antibodies protect infants against disease in the first months of life, but that protection comes at a cost: Their presence also interferes with the generation of a natural immune response to vaccination. As a result, most babies receive measles immunizations at the age of 12 to 15 months, when maternal antibodies are gone.

Years of studies have advanced the theory that maternal antibodies shield the measles virus so that cells that generate an immune response can't see the pathogen. If that were the case, little could be done to intervene.

But Ohio State University researchers have demonstrated an entirely different mechanism in an animal model, showing that maternal antibodies bind to a specific receptor that sends a message to stop activation of an immune response to vaccination. The scientists also determined that signals to the immune response can be manipulated, and they are already devising ways that vaccines could be designed to circumvent this natural process.

"In effect, we have found how maternal antibodies affect the off-switch in the immune response, and we have found a potential on-switch," said Stefan Niewiesk, associate professor of veterinary biosciences at Ohio State University and senior author of the study.

The research is published in the online First Edition of the journal Blood.

Under current pediatric practices, children receive measles vaccinations at age 12 to 15 months, and again when they are 5 years old. Maternal antibodies can be active in babies for up to nine months; this schedule is designed to offer protection after the decline of maternal antibodies.

"The maternal antibodies are high at birth, and go down over time. By age 1 year, the maternal antibodies are gone. So this vaccine schedule works quite well if protection is not so urgent. But there is a window of opportunity for measles to come in and infect. So we would like to be able to immunize earlier," said Niewiesk, also an investigator in Ohio State's Center for Microbial Interface Biology.

Niewiesk has been a leader in developing the cotton rat as an animal model for infectious diseases. The animal is susceptible to common human pathogens that affect the respiratory system, and Niewiesk's lab has developed antibodies and other substances that help to evaluate the immune response, which is similar to that found in humans.

As a result, researchers around the world have consulted with Niewiesk for years, using the animals to test vaccine candidates. Often, the experimental vaccines do not work in the presence of maternal antibodies. And even for the one vaccine that did work, the researchers couldn't explain why at the time.

So Niewiesk changed direction, setting aside vaccine testing and instead studying how the maternal antibodies influence the immune response to an antigen – in this case, the measles virus. With this new information, he and colleagues now have better information to guide the design of a measles vaccine that will be effective even while maternal antibodies are present.

In a normal immune response, white blood cells known as B cells grow and release antibodies that are prepared to fight a specific invader, known as an antigen. The B cells are called to action by B cell receptors on their surface; when the antigen binds to these B cell receptors, the cells get the message to proliferate and then secrete antibodies that are made strictly for the task of fending off the attacking virus.
For more information contact coordinator@nthrys.com